Short answer
Sight Sciences, Inc. (SGHT) filed an 8-K current report with the SEC on August 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Filing contains only signature certification, with no operating results or financial figures disclosed.
Sight Sciences, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Filing contains only signature certification, with no operating results or financial figures disclosed
- Signed August 5, 2026 by James Rodberg, Chief Financial and Accounting Officer
Item 7.01 · Regulation FD Disclosure
- Investor presentation posted August 5, 2026 under Regulation FD
- Exhibit 99.2 contains materials management expects to use with investors and analysts
- Presentation may be modified, making website materials relevant for updated company messaging
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue $23.4M, up 20% YoY; glaucoma revenue rose 8% while dry-eye revenue surged 704% to $2.7M
- Gross margin reached 91.4%, with dry-eye margin improving to 84.7% from 38.4% YoY
- Net loss narrowed to $4.4M, or $0.08 per share, from $11.9M and $0.23 per share
- Full-year revenue guidance raised to $88M–$92M; adjusted operating expense guidance reduced to $92M–$94M
- Reimbursement expansion added 4.1M dry-eye lives and 25M glaucoma lives through Aetna coverage; OMNI Ultra received FDA 510(k) clearance
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Sight Sciences, Inc. 8-K filings
Get the next SGHT 8-K as it lands
Follow SGHT for push alerts, or ask the research agent what this filing means.